RenovoRx Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.21next fiscal year
Monitoring Framework
Key Performance Indicators
Active Commercial Cancer Centers Quarterly16.0
Phase III TIGeR-PaC Randomized Patients Quarterly104.0
Quarterly Revenue Quarterly563KTarget: 3000000 to 4000000 (Full Year 2026)
Watch Items
- TIGeR-PaC Phase III Trial Enrollment CompletionTrigger: 114 randomized patientsAction: Verify completion of enrollment by the end of the first half of 2026 as scheduled.
- Cash Runway and Capital SufficiencyTrigger: Cash runway falling below 12 months of operating expensesAction: Assess the need for additional dilutive equity financing or strategic partnerships to fund operations into 2027.
- Commercial Adoption and Re-order RatesTrigger: Quarterly revenue growth flattening or active centers plateauingAction: Evaluate sales team performance and physician-to-physician advocacy programs to accelerate RenovoCath utilization.
Research as of 20 Jun 2026